Selank
Research draft Brain and mood research Best evidence grade A Human research reviewed, scope limited
Evidence design, not proof of benefit or product approval
Holds on this record
- No supplier batch has been matched to this record. A reviewer must record batch evidence before approval.
- Not marked ready for client selection in the library.
- No human administration guide. Study routes are research descriptions, not instructions.
- Research draft. Not released customer guidance.
The nine headings
Each heading opens a plain summary, then the deeper evidence and the sources behind it.
What it is A seven-link peptide derived from tuftsin.
Selank is a synthetic seven-link peptide based on tuftsin, a naturally occurring peptide. Its sequence is Thr–Lys–Pro–Arg–Pro–Gly–Pro. Researchers added three links to the tuftsin sequence while developing a peptide for anxiety research.
The standard Russian product is a nasal formulation. A supplier’s spray, a modified analogue and the product in a study need separate identity checks. This record establishes the named molecule from sources. It does not certify your bottle or a supplier batch.
Sources for this tile
- Volkova et al., 2016: Selank and GABA-related genes (Original full paper; 30 rats, gene-expression experiment · checked 2026-10-09)
- Selank: manufacturer instruction (Product instruction; formulation, schedule and exclusions · checked 2026-10-09)
Go deeper
From tuftsin to Selank Open the checked detail
The parent tuftsin chain has four amino acids. Selank adds Pro–Gly–Pro to make seven. A relationship to a natural peptide does not prove that the synthetic product is right for someone.
Sources
- Volkova et al., 2016: Selank and GABA-related genes (Original full paper; 30 rats, gene-expression experiment · checked 2026-10-09)
Formulation and batch match Open the checked detail
The cited label names Selank diacetate at 1.5 mg/mL. This liquid concentration is not the amount per spray. A pump’s measured volume and product strength are both needed to verify delivery.
Sources
- Selank: manufacturer instruction (Product instruction; formulation, schedule and exclusions · checked 2026-10-09)
The history The research teams and the clinical trail.
Selank came from Russian peptide research associated with Moscow State University, the Institute of Molecular Genetics and the Zakusov pharmacology institute. The manufacturer credits the work of I. P. Ashmarin, N. F. Myasoedov and S. B. Seredenin.
Its history describes tuftsin research in the 1990s and pharmacy availability in 2009. The earlier human comparison with medazepam was published in 2008. Development history explains where the question came from; the human results must still be read on their own terms.
Sources for this tile
- Selank: manufacturer history (Manufacturer chronology, not a clinical study · checked 2026-10-09)
- Selank: controlled anxiety comparison (Zozulia and colleagues · 2008 · Published abstract · checked 2026-10-09)
Go deeper
The research trail Open the checked detail
The manufacturer traces the work through tuftsin, the added peptide tail, clinical comparisons and the Russian nasal product. This is a manufacturer account. It is not independent proof of every marketed benefit.
Sources
- Selank: manufacturer history (Manufacturer chronology, not a clinical study · checked 2026-10-09)
How it works A GABA-related hypothesis, with its limits.
A leading research idea involves GABA, a chemical used in brain signalling. A rat experiment compared Selank, GABA and water, then measured genes involved in nerve-cell communication. Some patterns overlapped, which supports further study of a GABA-related mechanism.
That is animal evidence. It does not establish that a person has a GABA shortage or that Selank repairs a GABA receptor. A human anxiety paper also measured an enkephalin marker in blood. A marker association is not proof of the cause of someone’s symptoms.
Sources for this tile
- Volkova et al., 2016: Selank and GABA-related genes (Original full paper; 30 rats, gene-expression experiment · checked 2026-10-09)
- Selank: controlled anxiety comparison (Zozulia and colleagues · 2008 · Published abstract · checked 2026-10-09)
Each proposed mechanism
GABA-related gene-expression hypothesis
Rat experiment supports further study; clinical receptor action is not established.
Evidence note: C
Sources
- Volkova et al., 2016: Selank and GABA-related genes (Original full paper; 30 rats, gene-expression experiment · checked 2026-10-09)
Go deeper
GABA-related gene activity C C · Claim-specific evidence
C · Volkova and colleagues used 30 rats in Selank, GABA and water groups. Gene activity was measured at one and three hours. This experiment supports a mechanism hypothesis, not a proven clinical receptor action.
Sources
- Volkova et al., 2016: Selank and GABA-related genes (Original full paper; 30 rats, gene-expression experiment · checked 2026-10-09)
The enkephalin marker Open the checked detail
A trial design, mechanism still uncertain · The 2008 anxiety comparison measured the breakdown-related behaviour of an enkephalin marker in blood. A correlation with symptoms does not prove that changing this marker causes anxiety relief.
Sources
- Selank: controlled anxiety comparison (Zozulia and colleagues · 2008 · Published abstract · checked 2026-10-09)
What the mechanism does not say Open the checked detail
The checked pathway evidence cannot diagnose a client, predict a response or set a dose. The personal target must remain a question until supported by that person’s record and relevant human outcomes.
Sources
- Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)
What it helps Clinical anxiety research, not a promise for everyone.
Anxiety symptoms are the main clinical question in the checked Selank papers. The populations had defined anxiety-spectrum disorders or neurasthenia, a historical diagnosis involving fatigue and related symptoms. The outcomes were measured with symptom scales.
The papers provide early human signals, not a guarantee of calm, better sleep or better work for everyone. The 2014 comparison also had mixed findings across time: its active comparator reduced anxiety more at day 14, while later follow-up favoured Selank on the reported response count.
Sources for this tile
- Selank: controlled anxiety comparison (Zozulia and colleagues · 2008 · Published abstract · checked 2026-10-09)
- Medvedev et al., 2014: Selank versus phenazepam (Original full paper; 60 participants, open randomized active comparison · checked 2026-10-09)
Read this before you read a benefit into it
Laboratory and animal results describe what happened in that model. They are not proven healing in a person. Human studies name their own population, outcome and limits. Both are kept apart here on purpose.
Human research found for this product
Selank: controlled anxiety comparison A
| Proof grade | A |
|---|---|
| Design | Indexed as a randomized controlled trial; abstract review only |
| People or model | Generalized anxiety disorder or neurasthenia; PubMed gives 30 Selank and 32 medazepam |
| Number | 62 |
| Outcome measured | Anxiety scales and blood enkephalin marker |
| Result | The abstract reports similar anxiety relief with the two drugs and additional effects on fatigue with Selank. It gives no usable effect size. An abridged copy has conflicting allocation counts and is not merged. |
| Route in the study | Intranasal indexing; exact regimen not established from abstract |
| Duration | Not established from the original abstract |
| Risks noted | Not detailed in the original abstract |
| Personal regimen | Not set. A study regimen is not a personal instruction. |
Source
- Selank: controlled anxiety comparison (Zozulia and colleagues · 2008 · Published abstract · checked 2026-10-09)
Medvedev et al., 2014: Selank versus phenazepam A
| Proof grade | A |
|---|---|
| Design | Open randomized active-drug comparison; no placebo and no blinding |
| People or model | Adults aged 18–55 with anxiety-spectrum disorders; 30 per group |
| Number | 60 |
| Outcome measured | Anxiety scores, response and tolerability |
| Result | At day 14, mean anxiety-score reduction was 26.3% with Selank and 55% with phenazepam. Response was 5/30 versus 7/30. Day-21 response was 17/30 versus 9/30. Short, open follow-up limits the result. |
| Route in the study | Nasal product |
| Duration | 14 days of treatment, follow-up to day 21 |
| Risks noted | Better tolerability reported with Selank; small open trial cannot establish long-term safety |
| Regimen seen in the study | Selank 2.7 mg/day versus phenazepam 2 mg/day; study reference, not the current label schedule |
| Personal regimen | Not set. A study regimen is not a personal instruction. |
Source
- Medvedev et al., 2014: Selank versus phenazepam (Original full paper; 60 participants, open randomized active comparison · checked 2026-10-09)
Panikratova et al., 2020: Selank, Semax and brain networks A
| Proof grade | A |
|---|---|
| Design | Small placebo comparison; allocation and blinding details not established in the abstract |
| People or model | Healthy participants in separate Selank, Semax or placebo arms |
| Number | 52 |
| Outcome measured | Resting-state MRI connectivity |
| Result | The study measured brain-network changes, not reliable everyday anxiety relief, sleep improvement or the combined stack. |
| Route in the study | Route not established from the checked abstract |
| Duration | Scans before, then 5 and 20 minutes after administration |
| Risks noted | Not detailed in the checked abstract |
| Personal regimen | Not set. A study regimen is not a personal instruction. |
Source
- Panikratova et al., 2020: Selank, Semax and brain networks (Original abstract; separate treatment arms, not a combined stack · checked 2026-10-09)
Animal and laboratory records
Volkova et al., 2016: Selank and GABA-related genes C
| Proof grade | C |
|---|---|
| Result | Selank and GABA produced partially overlapping gene-expression patterns |
| Duration | Measurements at one and three hours |
| Personal regimen | Not set. A study regimen is not a personal instruction. |
Source
- Volkova et al., 2016: Selank and GABA-related genes (Original full paper; 30 rats, gene-expression experiment · checked 2026-10-09)
Go deeper
Anxiety symptoms A A · Claim-specific evidence
A · Small active-drug trials examined diagnosed anxiety groups. Their findings are relevant to that clinical question, with short duration and design limits. They are not proof of broad stress prevention in any buyer.
Sources
- Selank: controlled anxiety comparison (Zozulia and colleagues · 2008 · Published abstract · checked 2026-10-09)
- Medvedev et al., 2014: Selank versus phenazepam (Original full paper; 60 participants, open randomized active comparison · checked 2026-10-09)
Fatigue and daily function A A · Claim-specific evidence
The 2008 authors reported effects on fatigue as well as anxiety. The checked abstract provides no usable size of that added benefit. It does not establish a reliable energy effect in a healthy person.
Sources
- Selank: controlled anxiety comparison (Zozulia and colleagues · 2008 · Published abstract · checked 2026-10-09)
Sleep, memory and a combined stack A A · Claim-specific evidence
Those claims are not established by the checked clinical outcomes. A healthy-person MRI study used separate treatment arms. It does not prove a benefit from taking Selank and Semax together.
Sources
- Panikratova et al., 2020: Selank, Semax and brain networks (Original abstract; separate treatment arms, not a combined stack · checked 2026-10-09)
The research Each claim has a grade, a source and open limits.
The reviewed Selank evidence includes small human comparisons, a healthy-person scan study and animal mechanism work. Design matters: a randomized trial with an active drug and no blinding has different limits from a large blinded placebo trial.
The 2008 PubMed record and an abridged copy disagree about the allocation of their 62 participants. Their counts and dose details are not combined here. The FDA also flags missing safety information and product-quality concerns for compounded Selank acetate. These gaps remain visible beside the research.
Sources for this tile
- Selank: controlled anxiety comparison (Zozulia and colleagues · 2008 · Published abstract · checked 2026-10-09)
- Abridged 2008 Selank paper: conflicting group counts (Abridged copy; allocation differs from the PubMed abstract; not merged · checked 2026-10-09)
- FDA: compounding safety concerns (Current official notice; Semax and Selank acetate entries checked · checked 2026-10-09)
Overall state of the evidence
Status: scoped-human-evidence
Claim-specific evidence. No personal suitability or regimen approval. See individual study limitations.
Risk summary
The cited product instruction excludes intolerance to its ingredients, pregnancy, breastfeeding and age under 18. It lists unpleasant taste and allergy. A personal adverse-effect and stop plan is still blank. These product exclusions do not certify a compounded spray.
What is still open
- Exact supplier, formulation, pump delivery and batch match unverified
- Personal health record and suitability not assessed
- Human half-life and complete interaction review not established
- Scoped reviewed sources, not an exhaustive literature review
- 2008 group allocation conflict: PubMed 30/32 versus abridged copy 42/20
Checks a reviewer must finish first
- Exact formulation
- Anxiety history and medicines
- Trial design, route and adverse events
How to read the proof grades
- A: Controlled human trial. Note whether randomisation and blinding were confirmed.
- B: Small uncontrolled human study or chart review.
- C: Whole-animal intervention.
- D: Cell or other laboratory study.
- E: User reports. Kept separate and never substituted for a measured outcome.
- ungraded: Identity sources, official labels, notices, reviews and unverified claims are not assigned an efficacy grade.
Go deeper
How to read the proof Open the checked detail
A: controlled human trial. State whether it was blinded and randomized. B: small uncontrolled human study or chart review; a weak clinical comparison is marked with its design limits. C: whole-animal work. D: cells or other lab work. E: user reports.
A grade describes the kind of evidence for one claim. It does not grade every claim about a peptide or approve a product. Labels, history and regulatory reviews are named sources, not efficacy grades.
Sources
- Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)
A source conflict stays open Open the checked detail
PubMed reports 30 participants given Selank and 32 medazepam. An abridged copy reports 42 and 20. Both total 62. This review cannot resolve that difference and does not attach the copy’s dose or adverse-event count to the PubMed allocation.
Sources
- Selank: controlled anxiety comparison (Zozulia and colleagues · 2008 · Published abstract · checked 2026-10-09)
- Abridged 2008 Selank paper: conflicting group counts (Abridged copy; allocation differs from the PubMed abstract; not merged · checked 2026-10-09)
Safety and product quality Open the checked detail
FDA identifies gaps in human safety information for compounded Selank acetate, and potential immune reactions associated with aggregates and peptide-related impurities. These are concerns and missing evidence, not a measured probability of harm for a given person.
Sources
- FDA: compounding safety concerns (Current official notice; Semax and Selank acetate entries checked · checked 2026-10-09)
Researcher layer Open the checked detail
Sequence, origin and formulation sources are recorded. The trial records below separate design, population, result and observed dose. Human half-life, exact spray delivery, long-term outcomes and a complete interaction review are not established here.
No personal dose or cycle is approved. This is a scoped review of named sources, not an exhaustive Selank literature review.
Sources
- Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)
Research in people Three reviewed human records, with different outcomes.
The 2008 study compared Selank with medazepam in 62 people. A 2014 open randomized study compared it with phenazepam in 60 people. A separate 52-person imaging study examined Selank, Semax or placebo, each in its own arm.
The anxiety studies measured symptoms in people with defined disorders. The imaging study measured brain-network links. Those are different outcomes. Open a study for the actual result, course and missing details. An A grade marks a controlled design; it does not erase small size, lack of blinding or short follow-up.
Sources for this tile
- Selank: controlled anxiety comparison (Zozulia and colleagues · 2008 · Published abstract · checked 2026-10-09)
- Medvedev et al., 2014: Selank versus phenazepam (Original full paper; 60 participants, open randomized active comparison · checked 2026-10-09)
- Panikratova et al., 2020: Selank, Semax and brain networks (Original abstract; separate treatment arms, not a combined stack · checked 2026-10-09)
What people report
No user reports are recorded for this product. The library keeps human studies and user reports in separate places, so nothing is filled in here.
Each human record
Selank: controlled anxiety comparison A
| Proof grade | A |
|---|---|
| Design | Indexed as a randomized controlled trial; abstract review only |
| People or model | Generalized anxiety disorder or neurasthenia; PubMed gives 30 Selank and 32 medazepam |
| Number | 62 |
| Outcome measured | Anxiety scales and blood enkephalin marker |
| Result | The abstract reports similar anxiety relief with the two drugs and additional effects on fatigue with Selank. It gives no usable effect size. An abridged copy has conflicting allocation counts and is not merged. |
| Route in the study | Intranasal indexing; exact regimen not established from abstract |
| Duration | Not established from the original abstract |
| Risks noted | Not detailed in the original abstract |
| Personal regimen | Not set. A study regimen is not a personal instruction. |
Source
- Selank: controlled anxiety comparison (Zozulia and colleagues · 2008 · Published abstract · checked 2026-10-09)
Medvedev et al., 2014: Selank versus phenazepam A
| Proof grade | A |
|---|---|
| Design | Open randomized active-drug comparison; no placebo and no blinding |
| People or model | Adults aged 18–55 with anxiety-spectrum disorders; 30 per group |
| Number | 60 |
| Outcome measured | Anxiety scores, response and tolerability |
| Result | At day 14, mean anxiety-score reduction was 26.3% with Selank and 55% with phenazepam. Response was 5/30 versus 7/30. Day-21 response was 17/30 versus 9/30. Short, open follow-up limits the result. |
| Route in the study | Nasal product |
| Duration | 14 days of treatment, follow-up to day 21 |
| Risks noted | Better tolerability reported with Selank; small open trial cannot establish long-term safety |
| Regimen seen in the study | Selank 2.7 mg/day versus phenazepam 2 mg/day; study reference, not the current label schedule |
| Personal regimen | Not set. A study regimen is not a personal instruction. |
Source
- Medvedev et al., 2014: Selank versus phenazepam (Original full paper; 60 participants, open randomized active comparison · checked 2026-10-09)
Panikratova et al., 2020: Selank, Semax and brain networks A
| Proof grade | A |
|---|---|
| Design | Small placebo comparison; allocation and blinding details not established in the abstract |
| People or model | Healthy participants in separate Selank, Semax or placebo arms |
| Number | 52 |
| Outcome measured | Resting-state MRI connectivity |
| Result | The study measured brain-network changes, not reliable everyday anxiety relief, sleep improvement or the combined stack. |
| Route in the study | Route not established from the checked abstract |
| Duration | Scans before, then 5 and 20 minutes after administration |
| Risks noted | Not detailed in the checked abstract |
| Personal regimen | Not set. A study regimen is not a personal instruction. |
Source
- Panikratova et al., 2020: Selank, Semax and brain networks (Original abstract; separate treatment arms, not a combined stack · checked 2026-10-09)
Go deeper
Selank: controlled anxiety comparison A A · Claim-specific evidence
People: Generalized anxiety disorder or neurasthenia; PubMed gives 30 Selank and 32 medazepam. Total: 62. Design: Indexed as a randomized controlled trial; abstract review only.
Measured: Anxiety scales and blood enkephalin marker. The abstract reports similar anxiety relief with the two drugs and additional effects on fatigue with Selank. It gives no usable effect size. An abridged copy has conflicting allocation counts and is not merged.
Route: Intranasal indexing; exact regimen not established from abstract. Duration: Not established from the original abstract. Dose not established in this review.
Safety: Not detailed in the original abstract. Personal regimen: not approved.
Sources
- Selank: controlled anxiety comparison (Zozulia and colleagues · 2008 · Published abstract · checked 2026-10-09)
Medvedev et al., 2014: Selank versus phenazepam A A · Claim-specific evidence
People: Adults aged 18–55 with anxiety-spectrum disorders; 30 per group. Total: 60. Design: Open randomized active-drug comparison; no placebo and no blinding.
Measured: Anxiety scores, response and tolerability. At day 14, mean anxiety-score reduction was 26.3% with Selank and 55% with phenazepam. Response was 5/30 versus 7/30. Day-21 response was 17/30 versus 9/30. Short, open follow-up limits the result.
Route: Nasal product. Duration: 14 days of treatment, follow-up to day 21. Selank 2.7 mg/day versus phenazepam 2 mg/day; study reference, not the current label schedule
Safety: Better tolerability reported with Selank; small open trial cannot establish long-term safety. Personal regimen: not approved.
Sources
- Medvedev et al., 2014: Selank versus phenazepam (Original full paper; 60 participants, open randomized active comparison · checked 2026-10-09)
Panikratova et al., 2020: Selank, Semax and brain networks A A · Claim-specific evidence
People: Healthy participants in separate Selank, Semax or placebo arms. Total: 52. Design: Small placebo comparison; allocation and blinding details not established in the abstract.
Measured: Resting-state MRI connectivity. The study measured brain-network changes, not reliable everyday anxiety relief, sleep improvement or the combined stack.
Route: Route not established from the checked abstract. Duration: Scans before, then 5 and 20 minutes after administration. Dose not established in this review.
Safety: Not detailed in the checked abstract. Personal regimen: not approved.
Sources
- Panikratova et al., 2020: Selank, Semax and brain networks (Original abstract; separate treatment arms, not a combined stack · checked 2026-10-09)
Why it is for you Built from your own profile, once reviewed.
This tile begins with the person’s own words. It then links each concern to a named research question, the matching proof and the reasons to rule an option out. A goal such as better focus does not prove a damaged pathway.
No personal assessment or approved plan is recorded here. The shared library therefore does not call this peptide right for you. Your symptoms, medicines, history, baseline and stop wishes must be held in your own profile, outside this shared record.
Sources for this tile
- Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)
Not filled in for you yet
This heading is personal. It stays blank until your own intake is reviewed and a plan is agreed with you. Nobody else's reasons or results are shown here.
Go deeper
Your words and top three concerns Open the checked detail
Not filled in. The personal profile will preserve the original answers. Any interpretation must stay separate from what the person actually said.
Sources
- Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)
The target and matching evidence Open the checked detail
Not filled in. A proposed biological target needs support. The profile must name the relevant study population, outcome and limits before suggesting this option.
Sources
- Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)
Phase, baseline and stop wishes Open the checked detail
Not agreed. Record one change at a time, the starting measure, a check date and the person’s own stop wishes. Do not infer doses or cycles from a catalog entry.
Sources
- Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)
What you would notice Track symptoms and function, not a promised sensation.
If a reviewed plan targets anxiety, the meaningful check is a change in the person’s stated symptoms and daily function. The library cannot promise instant calm or tell you that a sensation proves the peptide is working. The human papers measured outcomes over days, not a reliable first-spray feeling.
Record a starting symptom measure, how it affects daily life, a review date and anything new or unwelcome. The label lists unpleasant taste and possible allergic reactions. The person’s own stop wishes and a reviewed response to adverse effects belong in the personal plan.
Sources for this tile
- Medvedev et al., 2014: Selank versus phenazepam (Original full paper; 60 participants, open randomized active comparison · checked 2026-10-09)
- Selank: manufacturer instruction (Product instruction; formulation, schedule and exclusions · checked 2026-10-09)
- Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)
Not filled in for you yet
This heading is personal. It stays blank until your own intake is reviewed and a plan is agreed with you. Nobody else's reasons or results are shown here.
Go deeper
Baseline and review A A · Claim-specific evidence
Use the same symptom and function measures before and after an approved change. The 2014 paper assessed people at days 7, 14 and 21; these are study dates, not an automatic personal follow-up schedule.
Sources
- Medvedev et al., 2014: Selank versus phenazepam (Original full paper; 60 participants, open randomized active comparison · checked 2026-10-09)
Rule-outs and stop signs Open the checked detail
The cited product instruction excludes intolerance to its ingredients, pregnancy, breastfeeding and age under 18. It lists unpleasant taste and allergy. A personal adverse-effect and stop plan is still blank. These product exclusions do not certify a compounded spray.
Sources
- Selank: manufacturer instruction (Product instruction; formulation, schedule and exclusions · checked 2026-10-09)
How it is taken Nasal reference, measured spray and course fields.
The reference product is nasal. Its current instruction specifies three administrations a day over 14 days. Combining its dispenser count with the manufacturer’s stated mass per unit gives 0.3 mg per administration and 0.9 mg per day. These are reference-product amounts.
At your stated 0.1 mg per spray, 0.3 mg corresponds to three sprays total per administration. This calculation does not verify the bottle or approve that schedule for you. The source does not name exact clock times. The higher 2.7 mg/day regimen in the 2014 trial remains a separate research reference.
Sources for this tile
- Selank: manufacturer instruction (Product instruction; formulation, schedule and exclusions · checked 2026-10-09)
- Selank: manufacturer information book, 2011 (Manufacturer reference; mass per dispenser unit and older schedule · checked 2026-10-09)
- Medvedev et al., 2014: Selank versus phenazepam (Original full paper; 60 participants, open randomized active comparison · checked 2026-10-09)
Routes seen in the research
- Nasal product references; study-specific route recorded separately
Dose and cycle fields in the library
These are blank on purpose. A personal amount, schedule, mixing or storage instruction is only written into an agreed plan after a reviewer checks the exact product.
| dose | Blank |
|---|---|
| unit | Blank |
| frequency | Blank |
| timeOfDay | Blank |
| foodTiming | Blank |
| route | Blank |
| injectionSite | Blank |
| cycleLength | Blank |
| restLength | Blank |
| titration | Blank |
| mixing | Blank |
| storage | Blank |
| expiryAfterMixing | Blank |
Go deeper
Your measured spray: milligrams and micrograms Open the checked detail
Calculation example using the stated 0.1 mg per full spray. That equals 100 micrograms (mcg). This amount per pump has not been checked against a bottle label.
At that stated strength: 3 sprays TOTAL = 0.3 mg = 300 mcg per administration. Two such administrations = 0.6 mg/day = 600 mcg/day. Three = 0.9 mg/day = 900 mcg/day. Three sprays in EACH nostril means 6 sprays total and doubles those amounts.
These are unit calculations. They do not set a personal schedule. Mass per spray is not the same as liquid volume per spray.
Reference timing and course Open the checked detail
Current product reference: 0.3 mg per administration, three administrations daily, 14 days. Exact clock times are not set in the instruction. Repeat-course timing in the label is conditional, not an automatic cycle to copy into a personal plan.
Sources
- Selank: manufacturer instruction (Product instruction; formulation, schedule and exclusions · checked 2026-10-09)
- Selank: manufacturer information book, 2011 (Manufacturer reference; mass per dispenser unit and older schedule · checked 2026-10-09)
The agreed personal administration card Open the checked detail
Approval status: no personal regimen approved in this record. Exact bottle, strength per pump, total sprays per administration, administrations per day, daily total, dates, review and stop signs are blank.
A published regimen stays in the reference layer. The app must not turn it into a personal instruction merely because its arithmetic matches a spray bottle.
Sources
- Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)
Storage and device Open the checked detail
The cited manufactured product is kept away from light, at or below 10°C, without freezing. Its label allows an opened bottle at or below 25°C for no more than 15 days. These limits do not establish the life of a different compounded spray. Its own bottle and pump instructions remain unchecked.
Sources
- Selank: manufacturer instruction (Product instruction; formulation, schedule and exclusions · checked 2026-10-09)
The higher trial dose is a separate record A A · Claim-specific evidence
The 2014 anxiety study used 2.7 mg/day for 14 days. That is not the current label reference calculated above. The app shows study doses as research facts, and keeps the agreed personal dose field blank.
Sources
- Medvedev et al., 2014: Selank versus phenazepam (Original full paper; 60 participants, open randomized active comparison · checked 2026-10-09)
Identity
| What it is made of | Selank is a synthetic seven-link peptide based on tuftsin, a naturally occurring peptide. Its sequence is Thr–Lys–Pro–Arg–Pro–Gly–Pro. Researchers added three links to the tuftsin sequence while developing a peptide for anxiety research. |
|---|---|
| Chain | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Chain length | 7 |
| Origin | Synthetic tuftsin analogue with Pro-Gly-Pro extension |
| Maker | Not recorded |
| Supplier batch matched | No. Not matched to a supplier batch. |
| Catalog sizes | 5mg to 11mg - Inherited reference only; stock and current product sizes unverified |
| Record checked on | 2026-10-09 |
Shared safety note
FDA flags immune reactions and impurities in several compounded peptides. Its notice also reports serious events in IV ipamorelin research, heart-rate and vessel-dilation reactions with CJC-1295, glucose concerns with GHRP-2/6, and serious case reports with melanotan II. Reports do not by themselves establish causation. This concerns proposed compounded products and routes, not every formulation worldwide.
Source
- FDA: compounding safety concerns (FDA · Official safety notice · checked 2026-10-08)